✦ LIBER ✦

Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma

✍ Scribed by Kensei Tobinai; Michinori Ogura; Dai Maruyama; Toshiki Uchida; Naokuni Uike; Ilseung Choi; Kenichi Ishizawa; Kuniaki Itoh; Kiyoshi Ando; Masafumi Taniwaki; Naomi Shimada; Ken Kobayashi

Book ID: 107619154
Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 345 KB
Volume: 92
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0707-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

Phase I and pharmacokinetic study of ben

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Kiyoshi Ando; Takashi Watana 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

Phase I and II pharmacokinetic and pharm

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

✍ Yoshiaki Ogawa; Kensei Tobinai; Michinori Ogura; Kiyoshi Ando; Takahide Tsuchiya 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views